(RTTNews) - Silo Pharma, Inc. (SILO), a development-stage biopharmaceutical company, on Wednesday, announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application 17/954,864, strengthening intellectual property protection for its lead asset, SPC-15, an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
This patent covers "Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females".
The new claims will expand upon the previous U.S. Patent 11,491,120 issued in February 2023.
Silo holds an exclusive license agreement with Columbia University to develop and commercialize SPC-15 globally.
CEO Eric Weisblum said, "This patent strengthens SPC-15's protection and broadens our technology rights as we advance our lead asset."
SPC-15 is a serotonin 5-HT4 receptor agonist that may qualify for the FDA's 505(b)(2) regulatory pathway, potentially accelerating approval.
Silo is collaborating with Columbia University on preclinical studies and holds exclusive rights to develop SPC-15 globally.
Silo Pharma is also advancing other treatments like SPC-14 for Alzheimer's and SPU-16 for multiple sclerosis as part of its CNS-focused pipeline.
SILO closed Tuesday's (Jan. 07, 2025) trading at $1.09, up 11.22%. In Premarket trading, the stock is up 83.71% at $2.04
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
